Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Tandem Diabetes securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Company Incident and Stock Impact - On August 7, 2025, Tandem Diabetes issued a press release regarding a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

New York, New York--(Newsfile Corp. - February 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Tandem Diabetes securities you may be entitled to compensation without payment of any out of pocket fees or cos ...

Market Overview - U.S. equity markets in Q4 2025 were influenced by optimism regarding potential monetary easing and caution related to economic growth and valuations [1] - Early gains were attributed to strong AI-related earnings and a rate cut by the US Federal Reserve in October, but sentiment cooled later due to mixed signals from the Fed [1] - Large caps rose 17.4% for the year and 2.4% in the quarter, while small caps gained 12.8% for the year and 2.2% in the quarter [1] - Value stocks outperformed growth stocks, returning 3.3% versus 1.2% for the quarter [1] Fund Performance - Meridian Growth Fund delivered a return of -0.39% (net) in Q4 2025, underperforming the Russell 2500 Growth Index's return of 0.33% [1] - The firm is monitoring factors that may impact market returns, including changes in monetary policy and the sustainability of AI investments due to high valuations among hyperscalers [1] Company Spotlight: Tandem Diabetes Care, Inc. - Tandem Diabetes Care, Inc. (NASDAQ:TNDM) was highlighted as a leading contributor in the Meridian Growth Fund's Q4 2025 investor letter [2] - The company specializes in technology solutions for diabetes management, particularly advanced insulin delivery systems [3] - Tandem's stock traded between $9.98 and $37.93 over the past 52 weeks, closing at $20.20 on January 26, 2026, with a market capitalization of $1.37 billion [2] - The stock experienced a one-month return of -10.26% but gained 33.77% over the last three months [2] - The company is well-positioned to capture market share in a growing addressable market, as many Type 1 diabetes patients still manage insulin manually [3]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Tandem Diabetes securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - A class action is being prepared by Rosen Law Firm to seek recovery of investor losses [2]. Group 2: Company Incident and Stock Impact - On August 7, 2025, Tandem Diabetes issued a press release regarding a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering substantial amounts for clients [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Information - Tandem Diabetes Care, Inc. is facing scrutiny after a press release on August 7, 2025, announced a voluntary medical device correction for select t:slim X2 insulin pumps, which could lead to a discontinuation of insulin delivery due to a speaker-related issue [3]. - Following the announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 2: Legal Actions - Investors who purchased Tandem Diabetes securities may be eligible for compensation through a class action lawsuit being prepared by Rosen Law Firm, with no out-of-pocket fees required [2]. - Interested investors can join the class action by submitting a form or contacting the law firm directly for more information [2]. Group 3: Rosen Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

Core Viewpoint - Tandem Diabetes Care, Inc. is a prominent player in the insulin pump technology market, showing resilience against competition from major companies like Medtronic and Insulet Corporation [1] Company Performance - RBC Capital maintains an "Outperform" rating for Tandem Diabetes, raising its price target from $25 to $30, reflecting confidence in the company's growth potential [2] - The average twelve-month price target from brokerages is approximately $22.44, slightly below the current stock price of $23.03, indicating a modest increase of 1.90% or $0.43 [3] Analyst Sentiment - Analyst ratings for Tandem Diabetes show mixed sentiment: one "sell," eleven "hold," and five "buy" recommendations [3] - Stifel Nicolaus initiated coverage with a "hold" rating and a target price of $15.00, while Canaccord Genuity reaffirmed a "buy" rating with a price objective of $24.00 [4] Stock Performance - The stock has fluctuated between a low of $22.40 and a high of $23.10 during the day, with a yearly peak of $38.28 and a low of $9.98 [5] - Tandem Diabetes Care has a market capitalization of approximately $1.56 billion and a trading volume of 120,728 shares on the NASDAQ exchange [5]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Legal Action - Shareholders who purchased Tandem Diabetes securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the allegations against Tandem Diabetes [2]. Group 2: Company Incident - On August 7, 2025, Tandem Diabetes issued a press release regarding a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Core Viewpoint - Tandem Diabetes Care is facing significant challenges, with a 43% decline in share price, and while it has innovative products, it needs to achieve consistent revenue growth to become an attractive investment [2][6]. Company Overview - Tandem Diabetes Care is a medical device company known for its innovative insulin pumps, particularly the t:slim X2, which has been a key growth driver [4]. - The company launched the Tandem Mobi, a smaller device that can be controlled via a smartphone app, in the U.S. last year [5]. Financial Performance - Despite its innovative offerings, Tandem Diabetes Care has experienced declining revenue growth over the past five years due to competition and lower demand for insulin pumps [5]. - The company remains unprofitable, and the current global trade environment may worsen its financial situation, particularly due to reliance on imported parts from countries like Mexico and China [6][8]. - The market capitalization of Tandem Diabetes Care is approximately $1 billion, with a gross margin of 53.23% [8]. Growth Potential - For Tandem Diabetes Care to be considered a viable investment, it needs to achieve mid-to-high teens revenue growth by expanding market share and encouraging current users to upgrade their devices [9]. - The introduction of the Tandem Mobi and other products in development could contribute to this growth strategy [10]. Investment Outlook - Currently, the stock is not recommended for purchase due to inconsistent revenue growth, competitive pressures, and industry challenges that may hinder profitability [10].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is focused on claims that Tandem Diabetes Care may have misled investors regarding its business practices [1]. - A class action is being prepared by Rosen Law Firm to seek recovery of investor losses, allowing affected shareholders to join without upfront costs [2]. Group 2: Incident Overview - On August 7, 2025, Tandem Diabetes issued a press release regarding a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements since 2013 [4].

Core Insights - Tandem Diabetes Care, Inc. (TNDM) is experiencing significant international expansion, which is expected to enhance growth in upcoming quarters. The company's strategic initiatives present favorable growth opportunities, although there are concerns regarding its heavy reliance on insulin pumps and the impact of macroeconomic challenges [1][9]. Financial Performance - Over the past year, TNDM's shares have declined by 38.7%, while the industry saw a minor decline of 0.3%. In contrast, the S&P 500 composite has increased by 16.4% during the same period. The company has a market capitalization of $1.15 billion and projects a growth rate of 59.2% for 2026 earnings, compared to 14.7% for the S&P 500 [2]. Strategic Developments - Tandem Diabetes is focusing on growth through acquisitions and investments in new technologies. The company has a competitive edge due to its rapid integration of Continuous Glucose Monitoring (CGM) systems, supported by partnerships with Dexcom and Abbott. The t:slim X2 pump is now compatible with Eli Lilly's ultra-rapid-acting insulin, Lyumjev [3][5]. - Operational improvements are being implemented to enhance efficiency, including streamlining processes and increasing automation. In Q3, Tandem achieved significant milestones by expanding pharmacy benefit coverage for Tandem Mobi to over 40% of U.S. covered lives and began selling t:slim supplies through pharmacy benefits [4]. International Market Focus - The International Diabetes Federation projects that by 2030, around 643 million people globally will have diabetes. Tandem's international expansion strategy aligns with this trend, allowing the company to capitalize on substantial market opportunities. In Q3, revenues outside the U.S. increased by 1.8% year-over-year, with approximately 9,000 pumps shipped across 25 markets [5][6][8]. Challenges - Macroeconomic uncertainties pose challenges for TNDM, making it difficult to predict product demand accurately. These conditions could lead to increased expenses and negatively affect financial performance. In Q3, the company reported a net loss of $21.2 million [9]. - TNDM's heavy dependence on insulin pumps is a concern, as these products accounted for 44.2% of worldwide sales in Q3 2025. Factors affecting market acceptance among insulin-dependent diabetes patients and healthcare providers could hinder the company's business and financial results [10]. Revenue Estimates - The Zacks Consensus Estimate for TNDM's 2025 loss per share has narrowed by 5 cents to $2.35 over the past 30 days. Revenue estimates for 2025 are projected at $1.00 billion, indicating a 9.9% increase from the previous year [11].